The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Savushkina O.K.

Tereshkina E.B.

Prokhorova T.A.

Vorobeva E.A.

Vishnevsky National Medical Research Center for Surgery of the Russia, Moscow, Russia

Boksha I.S.

Research Centre of Mental Health

Burbaeva G.Sh.

Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN, Moskva

Creatine kinase isoform B distribution in the brain in schizophrenia

Authors:

Savushkina O.K., Tereshkina E.B., Prokhorova T.A., Vorobeva E.A., Boksha I.S., Burbaeva G.Sh.

More about the authors

Read: 2124 times


To cite this article:

Savushkina OK, Tereshkina EB, Prokhorova TA, Vorobeva EA, Boksha IS, Burbaeva GSh. Creatine kinase isoform B distribution in the brain in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(9):62‑68. (In Russ.)
https://doi.org/10.17116/jnevro20161169162-68

Recommended articles:
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48
A role of transcription factors in pathogenic processes asso­ciated with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):49-54
Meta­bolic syndrome and anti­psychotic therapy of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):165-170
PANSS six-factor model. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):28-34
Clinical and immu­nological rela­tionships in patients with early schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50

References:

  1. Kann O. The interneuron energy hypothesis: Implications for brain disease. Neurobiol Dis. 2015;0969-9961(15):30025-5.  doi: 10.1016/j.nbd.2015.08.005
  2. Béard E, Braissant O. Synthesis and transport of creatine in the CNS: importance for cerebral functions. J Neurochem. 2010;115(2):297-313.  doi: 10.1111/j.1471-4159.2010.06935
  3. Andres RH, Ducray AD, Schlattner U, Wallimann T, Widmer HR Functions an effects of creatine in the central nervous system. Brain Res Bull. 2008;76(4):329-243.  doi: 10.1016/j.brainresbull.2008.02.035
  4. MacDonald ML, Naydenov A, Chu M, Matzilevich D, Konradi CВ. Decrease in creatine kinase messenger RNA expression in the hippocampus and dorsolateral prefrontal cortex in bipolar disorder. Вipolar Disord. 2006;8(3):255-264.  doi: 10.1111/j.1399-5618.2006.00302.x 
  5. Wood SJ, Berger G, Velakoulis D, Phillips LJ, McGorry PD, Yung AR, Desmond P, Pantelis C. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr Bull. 2003;29(4):831-843.  doi: 10.1093/oxfordjournals.schbul.a007049 
  6. Shi XF, Kondo DG, Sung YH, Hellem TL, Fiedler KK, Jeong EK, Huber RS, Renshaw PF. Frontal lobe bioenergetic metabolism in depressed adolescents with bipolar disorder: a phosphorus-31 magnetic resonance spectroscopy study. Bipolar Disord. 2012;14(6):607-617.  doi: 10.1111/j.1399-5618.2012.01040.x
  7. Smesny S, Gussew A, Biesel NJ, Schack S, Walther M, Rzanny R, Milleit B, Gaser C, Sobanski T, Schultz CC, Amminger P, Hipler UC, Sauer H, Reichenbach JR. Glutamatergic dysfunction linked to energy and membrane lipid metabolism in frontal and anterior cingulate cortices of never treated first-episode schizophrenia patients. Schizophr Res. 2015;168(1-2):322-329.  doi: 10.1016/j.schres.2015.07.013
  8. Du F, Cooper AJ, Thida T, Sehovic S, Lukas SE, Cohen BM, Zhang X, Ongür D. In vivo evidence for cerebral bioenergetic abnormalities in schizophrenia measured using 31P magnetization transfer spectroscopy. JAMA Psychiatry. 2014;71(1):19-27.  doi: 10.1001/jamapsychiatry.2013.2287
  9. Burbaeva GSh, Savushkina OK, Boksha IS. Comparative study of creatine kinase BB decrease in brain of patients with Alzheimer’s disease and schizophrenia. NATO Science Series, IOS Press; Netherlands. 2003;125-132.
  10. Wood PL, Holderman NR. Dysfunctional glycosynapses in schizophrenia: disease and regional specificity. Schizophr Res. 2015;166(1-3):235-237.  doi: 10.1016/j.schres.2015.05.017
  11. Diamond A. Close interrelation of motor development and cognitive development and of the cerebellum and prefrontal cortex. Child Dev. 2000;71(1):44-56.  doi: 10.1111/1467-8624.00117 
  12. Davis JM. Dose equivalence of the anti-psychotic drugs. J Psychiat Res. 1974;11:65-69.  doi: 10.1016/0022-3956(74)90071-5 
  13. Keutel HJ, Okabe K, Jacobs HK, Ziter F, Maland L, Kuby SA. Studies on adenosine triphosphate transphosphorylases. XI. Isolation of the crystalline adenosine triphosphate-creatine transphosphorylases from the muscle and brain of man, calf, and rabbit, and a praparation of their enzymatically active hybrids. Arch Biochem Biophys. 1972;150:648-678.
  14. Fiske CH, Subba Row Y. The colorimetric determination of phosphorus. J Biol Chem. 1925;66:375.
  15. Burbaeva GSh, Boksha IS, Tereshkina EB, Savushkina OK, Starodubtseva LI, Turishcheva MS. Glutamate metabolizing enzymes in prefrontal cortex of Alzheimer’s disease patients. Neurochemical Res. 2005;30(11):1443-1451. doi: 10.1007/s11064-005-8654-x
  16. Bolbecker AR, Petersen IT, Kent JS, Howell JM, O'Donnell BF, Hetrick WP. New Insights into the Nature of Cerebellar-Dependent Eyeblink Conditioning Deficits in Schizophrenia: A Hierarchical Linear Modeling Approach. Front Psychiatry. 2016;7:4.  doi: 10.3389/fpsyt.2016.00004
  17. Bottmer C, Bachmann S, Pantel J, Essig M, Amann M, Schad LR, Magnotta V. Schröder Reduced cerebellar volume and neurological soft signs in first-episode schizophrenia. J Psychiatry Res. 2005;140(3):239-250.  doi: 10.1016/j.pscychresns.2005.02.011 
  18. Rasser PE, Schall U, Peck G, Cohen M, Johnston P, Khoo K, Carr VJ, Ward PB, Thompson PM. Cerebellar grey matter deficits in first-episode schizophrenia mapped using cortical pattern matching. Neuroimage. 2010;53(4):1175-1180. doi: 10.1016/j.neuroimage.2010.07.018 
  19. Ichimiya T, Okubo Y, Suhara T, Sudo Y. Reduced volume of the cerebellar vermis in neuroleptic-naive schizophrenia. Biol Psychiatry. 2001;49(1):20-27.  doi: 10.1016/s0006-3223(00)01081-7 
  20. Burbaeva GSh, Aksenova MV, Makarenko IG. Decreased level of creatine kinase BB in the frontal cortex of Alzheimer patients. Dementia. 1992;3:91-94.  doi: 10.1159/000107000 
  21. Burbaeva GSh,. Boksha IS, Tereshkina EB, Savushkina OK, Prokhorova TA, Vorobyeva EA. Glutamate and GABA-Metabolizing Enzymes in Cerebellum in Alzheimer's Disease: Phosphate-Activated Glutaminase and Glutamic Acid Decarboxylase. Cerebellum. 2014;13(3):607-615.  doi: 10.1007/s12311-014-0573-4
  22. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D,Mimmack ML, Yolken RH, Webster MJ, Torrey EF, Bahn S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004;9(7):684-697, 643.  doi: 10.1038/sj.mp.4001511 

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.